Artrya Limited
Artrya Limited
Your view on AYA.AX
Overview
What the company does, where it operates, and who runs it.
About Artrya Limited
- Industry
- Medical - Healthcare Information Services
- Sector
- Healthcare
- CEO
- John Konstantopoulos
- Headquarters
- 1257 Hay Street, West Perth, WA, AU
- Industry
- Medical - Healthcare Information Services
- Sector
- Healthcare
- CEO
- John Konstantopoulos
- Headquarters
- 1257 Hay Street, West Perth, WA, AU
Artrya Limited is a medical technology firm that harnesses artificial intelligence (AI) to pinpoint individuals at risk of developing coronary artery disease. The company's key offering is Salix, a cloud-based software application.
Salix leverages Artrya's proprietary AI to automate the identification of coronary artery disease through the analysis of coronary computed tomography angiography (CCTA) scans. Founded in 2018, the company is headquartered in West Perth, Australia.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Artrya Limited. Starting points for Artrya Limited: EPS -AUD 0.15, beta 0.63 — an Medical - Healthcare Information Services name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Artrya Limited. Artrya Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Artrya Limited. Trailing twelve-month EPS for Artrya Limited stands at -AUD 0.15. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterJun 2027 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | −AUD 0.08 | −AUD 0.08 | −AUD 0.14 | −AUD 0.11 |
| Lowest estimate | −AUD 0.08 | −AUD 0.08 | −AUD 0.16 | −AUD 0.11 |
| Highest estimate | −AUD 0.08 | −AUD 0.08 | −AUD 0.12 | −AUD 0.09 |
| Number of analysts | 1 | 1 | 5 | 5 |
| A year ago | — | — | −AUD 0.171 | — |
| Growth vs a year ago | — | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterJun 2027 | This yearYear to Jun 2027 | Next yearYear to Jun 2028 |
|---|---|---|---|---|
| Average estimate | AUD 14000.00 | AUD 14000.00 | AUD 2.74M | AUD 16.68M |
| Lowest estimate | AUD 14000.00 | AUD 14000.00 | AUD 1.20M | AUD 12.50M |
| Highest estimate | AUD 14000.00 | AUD 14000.00 | AUD 6.02M | AUD 19.39M |
| Number of analysts | 1 | 1 | 4 | 5 |
| A year ago | — | — | AUD 28000.00 | — |
| Growth vs a year ago | — | — | +9685.7% | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Artrya Limited. Artrya Limited has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | |
|---|---|---|---|---|---|
| CGS.AXCogstate Limited | Healthcare | Medical - Healthcare Information Services | — | ||
| EIQ.AXEcho IQ Limited | Basic Materials | Other Precious Metals | — | ||
| ENL.AXEnlitic, Inc. | Healthcare | Medical - Healthcare Information Services | — | ||
| IME.AXImExHS Limited | Healthcare | Medical - Diagnostics & Research | — | ||
| M7T.AXMach7 Technologies Limited | Healthcare | Medical - Healthcare Information Services | — | ||
| PME.AXPro Medicus Limited | Healthcare | Medical - Healthcare Information Services | — | ||
| RHT.AXResonance Health Limited | Healthcare | Medical - Healthcare Information Services | — | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| TSTTFTripSitter Clinic Ltd. | Healthcare | OTC | $145,814 | ||
| TXG10x Genomics, Inc. | Healthcare | NASDAQ | $6.9B | ||
| UDOC.CNUnidoc Health Corp. | Healthcare | CNQ | $12.5M | ||
| UDOCFUnidoc Health Corp. | Healthcare | OTC | $7.6M | ||
| UMCNUMC, Inc. | Healthcare | OTC | $13.2M | ||
| UPHLUpHealth, Inc. | Healthcare | OTC | $5,679 | ||
| USPSUltimate Sports, Inc. | Healthcare | OTC | $679,298 | ||
| VASOVaso Corporation | Healthcare | OTC | $31.7M | ||
| VFX.AXVisionflex Fpo [vfx] | Healthcare | ASX | — | ||
| VHI.TOVitalhub Corp. | Healthcare | TSX | $421.8M | ||
| VHIBFVitalhub Corp. | Healthcare | OTC | $359.8M | ||
| VHL.AXVitasora Health Limited | Healthcare | ASX | — | ||
| Ticker | Fund | Fund assets | % of the fund |
|---|---|---|---|
| VXUSVanguard Total International Stock ETF | $163.2B in assets | 0.00% | |
| VEAVanguard FTSE Developed Markets ETF | $231.6B in assets | 0.00% | |
| VSSVanguard FTSE All-World ex-US Small-Cap ETF | $11.6B in assets | 0.01% | |
| SCHCSchwab International Small-Cap Equity ETF | $5.4B in assets | 0.01% | |
| VPLVanguard FTSE Pacific ETF | $9.0B in assets | 0.00% | |
| VTVanguard Total World Stock ETF | $81.8B in assets | 0.00% | |
| VIU.TOVanguard FTSE Developed All Cap ex North America Index ETF | $11.4B in assets | 0.00% | |
| VEQT.TOVanguard All-Equity ETF Portfolio | $17.6B in assets | 0.00% | |
Largest holders first, then the funds most concentrated in AYA.AX.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Artrya Limited.